POEMS (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal component and Skin changes) syndrome is a rare paraneoplastic syndrome secondary to plasma cell dyscrasia. As this disease is rare, no standard treatment has been developed. However, treatment options for this syndrome, such as the use of thalidomide, lenalidomide, bortezomib and bevacizumab (an antivascular endothelial growth factor (VEGF) Ab), have increased in the past decade. To date, high-dose melphalan followed by auto-SCT has been demonstrated to be the most effective treatment strategy. 7, 8 However, patients with poor mobilization cannot undergo auto-SCT. In addition, PBSC harvesting in patients with this syndrome is challenging, and these patients are at a higher risk than those with other hematological malignancies, because of poor performance status, morbidities associated with uncontrollable effusions and splenomegaly. 7 Here, we report two poorly mobilized cases of POEMS syndrome in which PBSCs were successfully harvested using G-CSF with plerixafor.
Case 1 A 43-year-old man was diagnosed with POEMS syndrome (IgA-l) and was referred to Chiba University Hospital in June, 2009. On admission, he was diagnosed with severe ascites, pleural effusion and neuropathy. His performance status was 4. He was treated with a combination therapy of thalidomide (300 mg/day), prednisolone and bevacizumab (5 mg/kg), which facilitated improvement in the systemic edema. PBSC harvesting was attempted using G-CSF alone (lenograstim; 10 mg/kg, 5 days) in June, 2010 using a blood cell separator (COBE Spectra, CaridianBCT, USA) for 4 h for each collection. However, the percent of CD34 þ cells of the apheresis products were only 0.1% on day 5 and 0.04% on day 6, and we failed to harvest sufficient stem cells (Figures 1 and 2) . A second PBSC harvest was planned 1 month later using G-CSF alone at the same dosage as the first collection after reducing thalidomide to 200 mg/day, but we failed to harvest sufficient CD34 þ cells (CD34 þ % of the product: 0.05%). A third attempt to harvest PBSC using G-CSF 10 mg/kg in combination with plerixafor was planned under thalidomide 200 mg/day. Plerixafor (240 mg/kg) was administered s.c. 11 h before apheresis. The percent of CD34 þ cells of the apheresis products from day 5 through day 8 were 0.2%, 0.25%, 0.33% and 0.17%, respectively, and we successfully harvested adequate CD34 þ cells (3.31 Â 10 6 /kg) over four apheresis procedures. There was no adverse event during PBSC harvesting. The patient underwent auto-SCT after a high dose of i.v. melphalan (100 mg/m 2 ), once daily on days 2 and 3 (total dose: 200 mg/m 2 ). Neutrophil and reticulocyte recoveries were recorded on days 16 and 13, respectively. Platelet recovery has not been more than 5 Â 10 4 /mL at the time of writing.
Case 2 A 55-year-old man with POEMS syndrome (IgG-l) was referred to our institution for auto-SCT, with ascites, pleural effusion, muscle weakness and neuropathy. His performance status was 4. He was treated with thalidomide (300 mg/day) and prednisolone, which facilitated improvement in the systemic edema and effusions. PBSC harvesting was attempted using G-CSF alone (10 mg/kg, 5 days). After the administration of G-CSF, his WBC count markedly increased and G-CSF dose was reduced. The WBC count had increased to 53 200/mL by day 5, but the percent of CD34 þ cells of the apheresis products on day 5 was only 0.05% and we could not harvest sufficient CD34 þ cells (Figures 1 and 2) . We then planned a PBSC harvest using G-CSF (5 mg/kg, 5 days) and plerixafor under the same dose of thalidomide. Plerixafor was administered using the same protocol as in Case 1. We successfully collected adequate PBSCs (total CD34 We successfully harvested PBSC in both patients using G-CSF with plerixafor. The apheresis procedures were safe, with no adverse events, and hematopoietic recovery was prompt. SDF-1a is a key factor in the homing of hematopoietic stem cells to BM, and is constitutively expressed in the BM microenvironment. Its receptor has been shown to be the chemokine receptor, CXCR4. Plerixafor is the first direct reversible antagonist of SDF-1a. Pharmacological inhibition of CXCR4 by plerixafor enhances the release of hematopoietic stem cells into the peripheral blood. 1 Perea et al. 9 reported that B20% of patients with myeloma could not mobilize sufficient PBSC for auto-SCT with G-CSF alone or G-CSF with chemotherapy. The rate of poor mobilization in POEMS syndrome in our institution was approximately the same (5/24, 21%). Suitable PBSC harvesting should be performed to facilitate optimum timing of safe and successful auto-SCT in patients with POEMS syndrome. We were able to harvest significantly higher numbers of CD34 þ cells in patients with POEMS syndrome using high-dose CY than with G-CSF alone. 10 However, these patients are at a higher risk during chemotherapy with high-dose CY than with G-CSF alone, and PBSC harvesting with high-dose CY is challenging because of poor performance statuses. Dispenzieri et al. 7 reported a case requiring intubation during PBSC harvesting. As the number of plasma cells in BM is low, chemotherapy is not always necessary before PBSC harvesting in POEMS syndrome compared with lymphoma or myeloma. Therefore, G-CSF monotherapy would be a suitable regimen for safe and efficient PBSC harvesting in these patients. As auto-SCT is an effective and pivotal treatment for this particular syndrome, plerixafor combined with G-CSF is a safe and effective strategy for poor mobilizers with G-CSF.
Recently, we analyzed factors associated with the efficiency of PBSC collection in POEMS syndrome patients undergoing auto-SCT and reported that splenomegaly was associated with a decrease in the efficacy of PBSC collection but VEGF was not. 10 Case 1 had huge splenomegaly before PBSC collection and it might have caused poor mobilization. The patient had poor platelet engraftment although enough number of CD34 þ cells was infused. As the patient had persistent splenomegaly even after auto-SCT, it might be related to the prolonged thrombocytopenia. Case 2 did not have splenomegaly before PBSC harvest. His WBC count rapidly increased after G-CSF injection, but the number of CD34 þ cells was low. As the patient had no history of chemotherapy except for thalidomide, there has been no obvious reason why Case 2 was a poor mobilizer.
In conclusion, plerixafor combined with G-CSF is safe and useful in poor mobilization patients with POEMS syndrome. Safe and efficient harvesting of PBSC with appropriately timed auto-SCT could improve the prognosis and quality of life in these patients. 
